Data Insights

Capivasertib by AstraZeneca for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Hormone-Sensitive Prostate Cancer

Data Insights

Capivasertib by AstraZeneca for Peritoneal Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Peritoneal Cancer

Data Insights

Capivasertib by AstraZeneca for Refractory Multiple Myeloma: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Refractory Multiple Myeloma

Data Insights

Capivasertib by AstraZeneca for Fallopian Tube Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Fallopian Tube Cancer

Data Insights

Capivasertib by AstraZeneca for Non-Small Cell Lung Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Non-Small Cell Lung Cancer

Data Insights

Capivasertib by AstraZeneca for Endometrial Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Endometrial Cancer

Data Insights

Capivasertib by AstraZeneca for Metastatic Breast Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Metastatic Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Metastatic Breast Cancer

Data Insights

Capivasertib by AstraZeneca for Lymphoma: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Lymphoma

Data Insights

Capivasertib by AstraZeneca for Prostate Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Prostate Cancer

Data Insights

Capivasertib by AstraZeneca for Ovarian Cancer: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Ovarian Cancer

Data Insights

Capivasertib by AstraZeneca for Solid Tumor: Likelihood of Approval

Capivasertib is under clinical development by AstraZeneca and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Solid Tumor